Few patients in this study had prior FLT3 inhibitor use, which may reflect the fact that the study’s enrollment period began before the widespread use of midostaurin [34] and quizartinib [35] during the induction and consolidation phases of patients with FLT3mut+ AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.